Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Carmen Dietvorst
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
BMI \> 30 kg/m2 or BMI \> 27 kg/m2 and at least one cardiometabolic risk factor (T2D, hypertension, dyslipidaemia)
Moderate to severe liver fibrosis, measured as liver stiffness by transient elastography (LSM \> 7.0 kPa and \< 13.6 kPa)
Aged 18-75 years
Written informed consent
You may not be if
An insufficient comprehension of the Dutch language (spoken and written)
Female who is pregnant, breast-feeding or intends to become pregnant
Participants with an established diagnosis of liver pathology like, but not limited to: Hepatitis B, Hepatitis C, Autoimmune hepatitis, Wilson's disease, Hemochromatosis, Primary biliary cholangitis, Primary sclerosing cholangitis, Alcoholic liver disease
History of liver transplant, or current placement on a liver transplant list
History of cirrhosis and/or hepatic decompensation, including ascites, hepatic encephalopathy or variceal bleeding
Participants with active HIV infection and/or treatment
Participants with diagnosed malignancies with or without active treatment
Participants with history or pre-existing renal disease (eGFR \<30 mL/min/1.73 m2)
Participants with corticosteroid induced diabetes (while still using corticosteroids)
Participants using GLP-1 agonists for less than 3 months or not yet on a stable dose
Participants using MAO-inhibitors, opioids and/or methadone (due to contraindication)
Known or suspected excessive alcohol consumption (\>30 grams/day for males or \>20 grams/day for females. One drink is equivalent to 10 grams of alcohol)
Previous or planned (during the trial period) obesity treatment with surgery. However, previous interventions that, due to reversal or removal, do not have any influence on the patient's weight, in the opinion of the investigator, are allowed.
Participants with a history or evidence of any other clinically significant condition or planned or expected procedure that in the opinion of the investigator, may compromise the patient's safety or ability to complete the study